IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend In Lung Cancer Patients

IDM Pharma, Inc. (Nasdaq: IDMI) announced updated results from the Phase 2 study of its investigational agent IDM-2101 which showed the vaccine was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in patients with non-small cell lung cancer (NSCLC) who were vaccinated with IDM-2101, compared to a parallel external control group of non-vaccinated patients. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 4th, 2007